Page 2 - Test Developer News Today

4.3.3 Diagnostics Moves Out of the Hospital 4.3.4 Disruption Looms 5. PCR Recent Developments 5.1.1 Importance of These Developments Scope Fluidics Secures €6.2M Supporting Rapid MDx Quidel Expects SARS-CoV-2 Testing Demand to Continue Through 2022, and Beyond Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection Fluidigm Saliva Test for SARS-CoV-2 Uses Extraction-free RT-PCR Visby Medical Gonorrhea Test Wins $19M AMR Diagnostic Competition HelixBind Receives $3M NIH Gran...

4.3.2 Shifting Role of Diagnostics 4.3.3 Multiplexing and Foundation One 4.3.4 The Disruption Dynamic 4.3.6 The Next Five Years 5. Cancer Immuno-Oncology Diagnostics Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section Qiagen Expands Immuno-Oncology Portfolio IncellDx Awarded PD-L1 Detection Patent FDA Approves CDx for Trastuzumab Promega Nabs CE Mark for Microsatellite Instability IVD ...

4.3.3 Diagnostics Moves Out of the Hospital 4.3.4 Disruption Looms 5. PCR Recent Developments 5.1.1 Importance of These Developments 5.1.2 How to Use This Section Scope Fluidics Secures ?6.2M Supporting Rapid MDx Quidel Expects SARS-CoV-2 Testing Demand to Continue Through 2022, and Beyond Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection Fluidigm Saliva Test for SARS-CoV-2 Uses Extraction-free RT-PCR Visby Medical Gonorrhea Test Wins $19M AMR Diagnostic Competition Hel...

Share this article Share this article ResearchAndMarkets.coms offering. Sepsis was killing over 30 million people a year with no definitive diagnostic in hand. And now the COVID-19 Pandemic has increased the sepsis death toll. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade. It is not clear who will be the winner, but the stakes are global and large. Emergency life-saving diagnostics can command a premium in the market, especiall...